D H Walker
11 works · 621 citations · h-index 7
Top works
- Periodic changes in phosphorylation of the Xenopus cdc25 phosphatase regulate its activity.
- Role for cyclin A in the dependence of mitosis on completion of DMA replication
- Activation of p34cdc2 kinase by cyclin A.
- Oxindole-Based Inhibitors of Cyclin-Dependent Kinase 2 (CDK2): Design, Synthesis, Enzymatic Activities, and X-ray Crystallographic Analysis
- Purification and characterization of a phosphatidylinositol kinase from A431 cells
- Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors
- Phosphatidylinositol kinase is activated in membranes derived from cells treated with epidermal growth factor.
- Cdc25 regulates the phosphorylation and activity of the Xenopus cdk2 protein kinase complex.
- Multiple roles for protein phosphatase 1 in regulating the Xenopus early embryonic cell cycle.
- Rapid Development of Affinity Matured Monoclonal Antibodies Using RIMMS
- Substrate specificity and kinetic mechanism of human placental insulin receptor/kinase
- Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor
- Mcl-1 Stability Determines Mitotic Cell Fate of Human Multiple Myeloma Tumor Cells Treated with the Kinesin Spindle Protein Inhibitor ARRY-520
- SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples
- Small-Molecule Inhibitors of Cyclin-Dependent Kinases: Molecular Tools and Potential Therapeutics
- ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models.
- A Phase 1 and 2 study of Filanesib alone and in combination with low‐dose dexamethasone in relapsed/refractory multiple myeloma
- Misregulated expression of the cyclin dependent kinase 2 protein in human fibroblasts is accompanied by the inability to maintain a G2 arrest following DNA damage.
- Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors
- Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma